{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T13:45:11Z","timestamp":1790343911965,"version":"4.1.0"},"reference-count":73,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,3,2]],"date-time":"2025-03-02T00:00:00Z","timestamp":1740873600000},"content-version":"am","delay-in-days":335,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100000002","name":"NIH","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["bmn.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Drug Discovery Today"],"published-print":{"date-parts":[[2024,4]]},"DOI":"10.1016\/j.drudis.2024.103922","type":"journal-article","created":{"date-parts":[[2024,2,20]],"date-time":"2024-02-20T15:55:13Z","timestamp":1708444513000},"page":"103922","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":26,"title":["Orphan GPR52 as an emerging neurotherapeutic target"],"prefix":"10.1016","volume":"29","author":[{"given":"Saghir","family":"Ali","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pingyuan","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryan E.","family":"Murphy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John A.","family":"Allen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jia","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.drudis.2024.103922_b0005","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1038\/nrm908","article-title":"Seven-transmembrane receptors","volume":"3","author":"Pierce","year":"2002","journal-title":"Nat Rev Mol Cell Biol"},{"key":"10.1016\/j.drudis.2024.103922_b0010","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1021\/acs.jmedchem.6b01453","article-title":"Recent advances in structure-based drug design targeting class A G protein-coupled receptors utilizing crystal structures and computational simulations","volume":"61","author":"Lee","year":"2018","journal-title":"J Med Chem"},{"key":"10.1016\/j.drudis.2024.103922_b0015","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1146\/annurev-pharmtox-010510-100553","article-title":"Strategies to discover unexpected targets for drugs active at G protein-coupled receptors","volume":"51","author":"Allen","year":"2011","journal-title":"Annu Rev Pharmacol Toxicol"},{"key":"10.1016\/j.drudis.2024.103922_b0020","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1038\/nrd3320","article-title":"G protein-coupled receptors: novel targets for drug discovery in cancer","volume":"10","author":"Lappano","year":"2011","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.drudis.2024.103922_b0025","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1021\/acschemneuro.8b00572","article-title":"Orphan receptor GPR88 as an emerging neurotherapeutic target","volume":"10","author":"Ye","year":"2019","journal-title":"ACS Chem Neurosci"},{"key":"10.1016\/j.drudis.2024.103922_b0030","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1021\/acs.jmedchem.8b00875","article-title":"Allosteric modulation of class A GPCRs: targets, agents, and emerging concepts","volume":"62","author":"Wold","year":"2019","journal-title":"J Med Chem"},{"key":"10.1016\/j.drudis.2024.103922_b0035","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1124\/mol.117.111062","article-title":"G protein-coupled receptors as targets for approved drugs: how many targets and how many drugs?","volume":"93","author":"Sriram","year":"2018","journal-title":"Mol Pharmacol"},{"key":"10.1016\/j.drudis.2024.103922_b0040","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/j.cell.2017.11.033","article-title":"Pharmacogenomics of GPCR drug targets","volume":"172","author":"Hauser","year":"2018","journal-title":"Cell"},{"key":"10.1016\/j.drudis.2024.103922_b0045","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/j.cell.2020.03.003","article-title":"Impact of GPCR structures on drug discovery","volume":"181","author":"Congreve","year":"2020","journal-title":"Cell"},{"key":"10.1016\/j.drudis.2024.103922_b0050","article-title":"A systematic survey of human tissue-specific gene expression and splicing reveals new opportunities for therapeutic target identification and evaluation","author":"Yang","year":"2018","journal-title":"bioRxiv"},{"key":"10.1016\/j.drudis.2024.103922_b0055","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1038\/s41573-020-0062-z","article-title":"Advances in therapeutic peptides targeting G protein-coupled receptors","volume":"19","author":"Davenport","year":"2020","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.drudis.2024.103922_b0060","doi-asserted-by":"crossref","DOI":"10.1016\/j.drudis.2023.103698","article-title":"Opportunities and challenges in drug discovery targeting the orphan receptor GPR12","volume":"28","author":"Wang","year":"2023","journal-title":"Drug Discov Today"},{"key":"10.1016\/j.drudis.2024.103922_b0065","doi-asserted-by":"crossref","first-page":"3318","DOI":"10.1021\/acschemneuro.3c00479","article-title":"Orphan G protein-coupled receptor GPR37 as an emerging therapeutic target","volume":"14","author":"Bolinger","year":"2023","journal-title":"ACS Chem Neurosci"},{"key":"10.1016\/j.drudis.2024.103922_b0070","doi-asserted-by":"crossref","first-page":"1950","DOI":"10.1038\/s41467-018-04342-1","article-title":"Optical functionalization of human Class A orphan G-protein-coupled receptors","volume":"9","author":"Morri","year":"2018","journal-title":"Nat Commun"},{"key":"10.1016\/j.drudis.2024.103922_b0075","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1038\/aps.2011.210","article-title":"Orphan G protein-coupled receptors (GPCRs): biological functions and potential drug targets","volume":"33","author":"Tang","year":"2012","journal-title":"Acta Pharmacol Sin"},{"key":"10.1016\/j.drudis.2024.103922_b0080","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1016\/j.biopha.2017.12.056","article-title":"Orphan G protein-coupled receptors: the role in CNS disorders","volume":"98","author":"Alavi","year":"2018","journal-title":"Biomed Pharmacother"},{"key":"10.1016\/j.drudis.2024.103922_b0085","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1016\/S0169-328X(98)00277-0","article-title":"Identification and cloning of three novel human G protein-coupled receptor genes GPR52, \u03a8GPR53 and GPR55: GPR55 is extensively expressed in human brain","volume":"64","author":"Sawzdargo","year":"1999","journal-title":"Mol Brain Res"},{"key":"10.1016\/j.drudis.2024.103922_b0090","series-title":"Investigating the role of schizophrenia-associated gene expression in the developing human brain using Machine Learning","author":"Kelly","year":"2021"},{"key":"10.1016\/j.drudis.2024.103922_b0095","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1038\/s41588-018-0059-2","article-title":"Common schizophrenia alleles are enriched in mutation-intolerant genes and in regions under strong background selection","volume":"50","author":"Pardi\u00f1as","year":"2018","journal-title":"Nat Genet"},{"key":"10.1016\/j.drudis.2024.103922_b0100","doi-asserted-by":"crossref","first-page":"e90134","DOI":"10.1371\/journal.pone.0090134","article-title":"Anatomical transcriptome of G protein-coupled receptors leads to the identification of a novel therapeutic candidate GPR52 for psychiatric disorders","volume":"9","author":"Komatsu","year":"2014","journal-title":"PloS One"},{"key":"10.1016\/j.drudis.2024.103922_b0105","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1038\/ng.2653","article-title":"The Genotype-Tissue Expression (GTEx) project","volume":"45","author":"Lonsdale","year":"2013","journal-title":"Nat Genet"},{"key":"10.1016\/j.drudis.2024.103922_b0110","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1038\/s41586-020-2019-0","article-title":"Structural basis of ligand recognition and self-activation of orphan GPR52","volume":"579","author":"Lin","year":"2020","journal-title":"Nature"},{"key":"10.1016\/j.drudis.2024.103922_b0115","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1038\/nature10361","article-title":"Crystal structure of the \u03b22 adrenergic receptor\u2013Gs protein complex","volume":"477","author":"Rasmussen","year":"2011","journal-title":"Nature"},{"key":"10.1016\/j.drudis.2024.103922_b0120","doi-asserted-by":"crossref","first-page":"e35946","DOI":"10.7554\/eLife.35946","article-title":"Cryo-EM structure of the adenosine A2A receptor coupled to an engineered heterotrimeric G protein","volume":"7","author":"Garcia-Nafria","year":"2018","journal-title":"eLife"},{"key":"10.1016\/j.drudis.2024.103922_b0125","doi-asserted-by":"crossref","first-page":"e0138463","DOI":"10.1371\/journal.pone.0138463","article-title":"Constitutive activity among orphan Class-A G protein coupled receptors","volume":"10","author":"Martin","year":"2015","journal-title":"PloS One"},{"key":"10.1016\/j.drudis.2024.103922_b0130","doi-asserted-by":"crossref","first-page":"13951","DOI":"10.1021\/acs.jmedchem.0c01498","article-title":"Discovery of potent and brain-penetrant GPR52 agonist that suppresses psychostimulant behavior","volume":"63","author":"Wang","year":"2020","journal-title":"J Med Chem"},{"key":"10.1016\/j.drudis.2024.103922_b0135","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1038\/d41586-020-00411-y","article-title":"A self-activating orphan receptor","volume":"579","author":"Krumm","year":"2020","journal-title":"Nature"},{"key":"10.1016\/j.drudis.2024.103922_b0140","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1124\/jpet.117.242925","article-title":"FTBMT, a novel and selective GPR52 agonist, demonstrates antipsychotic-like and procognitive effects in rodents, revealing a potential therapeutic agent for schizophrenia","volume":"363","author":"Nishiyama","year":"2017","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1016\/j.drudis.2024.103922_b0145","doi-asserted-by":"crossref","first-page":"2077","DOI":"10.1021\/acschemneuro.0c00199","article-title":"\u03b2-Arrestin-2-dependent mechanism of GPR52 signaling in frontal cortical neurons","volume":"11","author":"Hatzipantelis","year":"2020","journal-title":"ACS Chem Neurosci"},{"key":"10.1016\/j.drudis.2024.103922_b0150","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1139\/cjpp-2023-0199","article-title":"The non-nutritive sweetener sucralose increases \u03b2-arrestin signaling at the constitutively active orphan G protein-coupled receptor GPR52","volume":"102","author":"Power","year":"2024","journal-title":"Can J Physiol Pharmacol"},{"key":"10.1016\/j.drudis.2024.103922_b0155","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1124\/pr.110.002642","article-title":"The physiology, signaling, and pharmacology of dopamine receptors","volume":"63","author":"Beaulieu","year":"2011","journal-title":"Pharmacol Rev"},{"key":"10.1016\/j.drudis.2024.103922_b0160","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/978-1-4939-2569-8_1","article-title":"Rab family of GTPases","volume":"1298","author":"Li","year":"2015","journal-title":"Methods Mol Biol"},{"key":"10.1016\/j.drudis.2024.103922_b0165","doi-asserted-by":"crossref","first-page":"e05449","DOI":"10.7554\/eLife.05449","article-title":"A striatal-enriched intronic GPCR modulates huntingtin levels and toxicity","volume":"4","author":"Yao","year":"2015","journal-title":"eLife"},{"key":"10.1016\/j.drudis.2024.103922_b0170","doi-asserted-by":"crossref","first-page":"2066","DOI":"10.1021\/acschemneuro.0c00197","article-title":"In the loop: extrastriatal regulation of spiny projection neurons by GPR52","volume":"11","author":"Spark","year":"2020","journal-title":"ACS Chem Neurosci"},{"key":"10.1016\/j.drudis.2024.103922_b0175","doi-asserted-by":"crossref","first-page":"e0118510","DOI":"10.1371\/journal.pone.0118510","article-title":"Temporal and spatial transcriptional fingerprints by antipsychotic or propsychotic drugs in mouse brain","volume":"10","author":"Sakuma","year":"2015","journal-title":"PloS One"},{"key":"10.1016\/j.drudis.2024.103922_b0180","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1016\/j.brainres.2017.05.031","article-title":"Genetic deletion of GPR52 enhances the locomotor-stimulating effect of an adenosine A2A receptor antagonist in mice: a potential role of GPR52 in the function of striatopallidal neurons","volume":"1670","author":"Nishiyama","year":"2017","journal-title":"Brain Res"},{"key":"10.1016\/j.drudis.2024.103922_b0185","doi-asserted-by":"crossref","first-page":"5226","DOI":"10.1021\/jm5002919","article-title":"Discovery of the first potent and orally available agonist of the orphan G-protein-coupled receptor 52","volume":"57","author":"Setoh","year":"2014","journal-title":"J Med Chem"},{"key":"10.1016\/j.drudis.2024.103922_b0190","doi-asserted-by":"crossref","first-page":"3098","DOI":"10.1016\/j.bmc.2017.03.064","article-title":"Design, synthesis, and pharmacological evaluation of 4-azolyl-benzamide derivatives as novel GPR52 agonists","volume":"25","author":"Tokumaru","year":"2017","journal-title":"Bioorg Med Chem"},{"key":"10.1016\/j.drudis.2024.103922_b0195","doi-asserted-by":"crossref","first-page":"1598","DOI":"10.1016\/j.bmc.2018.02.005","article-title":"Design and synthesis of 1-(1-benzothiophen-7-yl)-1H-pyrazole, a novel series of G protein-coupled receptor 52 (GPR52) agonists","volume":"26","author":"Nakahata","year":"2018","journal-title":"Bioorg Med Chem"},{"key":"10.1016\/j.drudis.2024.103922_b0200","doi-asserted-by":"crossref","first-page":"S924","DOI":"10.1016\/S0924-977X(17)31641-3","article-title":"GPR52 agonists represent a novel approach to treat psychotic disorders and improve cognitive function","volume":"27","author":"Grottick","year":"2017","journal-title":"Eur Neuropsychopharmacol"},{"key":"10.1016\/j.drudis.2024.103922_b0205","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopsych.2017.02.1078","article-title":"GPR52 agonists represent a novel approach to treat cognitive deficits associated with schizophrenia","volume":"81","author":"Grottick","year":"2017","journal-title":"Biol Psychiatry"},{"key":"10.1016\/j.drudis.2024.103922_b0210","doi-asserted-by":"crossref","first-page":"1365","DOI":"10.2174\/1568026619666190712210903","article-title":"Advances in dopamine D1 receptor ligands for neurotherapeutics","volume":"19","author":"Felsing","year":"2019","journal-title":"Curr Top Med Chem"},{"key":"10.1016\/j.drudis.2024.103922_b0215","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.tins.2007.03.008","article-title":"D1 and D2 dopamine-receptor modulation of striatal glutamatergic signaling in striatal medium spiny neurons","volume":"30","author":"Surmeier","year":"2007","journal-title":"Trends Neurosci"},{"key":"10.1016\/j.drudis.2024.103922_b0220","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1016\/j.bbr.2007.08.012","article-title":"Lurasidone reverses MK-801-induced impairment of learning and memory in the Morris water maze and radial-arm maze tests in rats","volume":"186","author":"Enomoto","year":"2008","journal-title":"Behav Brain Res"},{"key":"10.1016\/j.drudis.2024.103922_b0225","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1016\/j.molcel.2018.07.032","article-title":"mHTT seeding activity: a marker of disease progression and neurotoxicity in models of Huntington's disease","volume":"71","author":"Ast","year":"2018","journal-title":"Mol Cell"},{"key":"10.1016\/j.drudis.2024.103922_b0230","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.1016\/j.neuron.2012.05.009","article-title":"Sustained therapeutic reversal of Huntington's disease by transient repression of huntingtin synthesis","volume":"74","author":"Kordasiewicz","year":"2012","journal-title":"Neuron"},{"key":"10.1016\/j.drudis.2024.103922_b0235","doi-asserted-by":"crossref","first-page":"2719","DOI":"10.1172\/JCI92087","article-title":"CRISPR\/Cas9-mediated gene editing ameliorates neurotoxicity in mouse model of Huntington's disease","volume":"127","author":"Yang","year":"2017","journal-title":"J Clin Invest"},{"key":"10.1016\/j.drudis.2024.103922_b0240","doi-asserted-by":"crossref","first-page":"1820","DOI":"10.1096\/fj.12-219220","article-title":"A novel human embryonic stem cell-derived Huntington's disease neuronal model exhibits mutant huntingtin (mHTT) aggregates and soluble mHTT-dependent neurodegeneration","volume":"27","author":"Lu","year":"2013","journal-title":"FASEB J"},{"key":"10.1016\/j.drudis.2024.103922_b0245","doi-asserted-by":"crossref","first-page":"1782","DOI":"10.1093\/brain\/awy081","article-title":"Targeting Gpr52 lowers mutant HTT levels and rescues Huntington's disease-associated phenotypes","volume":"141","author":"Song","year":"2018","journal-title":"Brain"},{"key":"10.1016\/j.drudis.2024.103922_b0250","article-title":"1-Heteroaryl-indoline-4-carboxamides as modulators of GPR52 useful for the treatment or prevention of disorders related thereto","author":"Xiong","year":"2016","journal-title":"Patent"},{"key":"10.1016\/j.drudis.2024.103922_b0255","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1021\/acsmedchemlett.3c00052","article-title":"The identification of GPR52 agonist HTL0041178, a potential therapy for schizophrenia and related psychiatric disorders","volume":"14","author":"Poulter","year":"2023","journal-title":"ACS Med Chem Lett"},{"key":"10.1016\/j.drudis.2024.103922_b0260","unstructured":"Stott, L.A. et al. Characterisation of [3H]-HTL45725, a novel radioligand for the orphan receptor GPR52 (Poster 18). Presented at Drug Discovery 2021, Liverpool, UK, 19\u221220 October 2021. Available at https:\/\/www.myeventflo.com\/event-lecture.aspx?m=4&evID=2374&lectID=24150"},{"key":"10.1016\/j.drudis.2024.103922_b0265","doi-asserted-by":"crossref","DOI":"10.1016\/j.nsa.2022.100412","article-title":"Effect of HTL0045725, a selective agonist of the orphan receptor GPR52, on kinase and transcription factor phosphorylation in striatal neurons","volume":"1","author":"Sergeev","year":"2022","journal-title":"Neurosci Applied"},{"key":"10.1016\/j.drudis.2024.103922_b0270","article-title":"Sosei Heptares doses first subject in phase I trial with HTL0048149, a first-in-class GPR52 agonist for schizophrenia","author":"Heptares","year":"2023","journal-title":"Sosei Heptares"},{"key":"10.1016\/j.drudis.2024.103922_b0275","doi-asserted-by":"crossref","first-page":"3275","DOI":"10.1021\/acschembio.0c00867","article-title":"Targeted proteomics combined with affinity mass spectrometry analysis reveals antagonist E7 acts as an intracellular covalent ligand of orphan receptor GPR52","volume":"15","author":"Ma","year":"2020","journal-title":"ACS Chem Biol"},{"key":"10.1016\/j.drudis.2024.103922_b0280","doi-asserted-by":"crossref","first-page":"12470","DOI":"10.1038\/ncomms12470","article-title":"Divergent synthesis and identification of the cellular targets of deoxyelephantopins","volume":"7","author":"Lagoutte","year":"2016","journal-title":"Nat Commun"},{"key":"10.1016\/j.drudis.2024.103922_b0285","doi-asserted-by":"crossref","first-page":"941","DOI":"10.1021\/acs.jmedchem.0c01133","article-title":"GPR52 antagonist reduces Huntingtin levels and ameliorates Huntington's disease-related phenotypes","volume":"64","author":"Wang","year":"2021","journal-title":"J Med Chem"},{"key":"10.1016\/j.drudis.2024.103922_b0290","doi-asserted-by":"crossref","DOI":"10.1016\/j.heliyon.2021.e07201","article-title":"Characterisation of inverse agonism of the orphan-G protein-coupled receptor GPR52 by cannabinoid ligands Cannabidiol and O-1918","volume":"7","author":"Stott","year":"2021","journal-title":"Heliyon"},{"key":"10.1016\/j.drudis.2024.103922_b0295","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/j.drudis.2014.09.015","article-title":"Evolutions in fragment-based drug design: the deconstruction-reconstruction approach","volume":"20","author":"Chen","year":"2015","journal-title":"Drug Discov Today"},{"key":"10.1016\/j.drudis.2024.103922_b0300","doi-asserted-by":"crossref","first-page":"998","DOI":"10.2174\/1568026618666180813152921","article-title":"Structure-based drug design strategies and challenges","volume":"18","author":"Wang","year":"2018","journal-title":"Curr Top Med Chem"},{"key":"10.1016\/j.drudis.2024.103922_b0305","doi-asserted-by":"crossref","first-page":"2284","DOI":"10.2174\/1568026619666181130134250","article-title":"Counting on fragment based drug design approach for drug discovery","volume":"18","author":"Kashyap","year":"2018","journal-title":"Curr Top Med Chem"},{"key":"10.1016\/j.drudis.2024.103922_b0310","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1016\/j.ejmech.2013.01.023","article-title":"Fragment-based drug design and identification of HJC0123, a novel orally bioavailable STAT3 inhibitor for cancer therapy","volume":"62","author":"Chen","year":"2013","journal-title":"Eur J Med Chem"},{"key":"10.1016\/j.drudis.2024.103922_b0315","doi-asserted-by":"crossref","first-page":"5242","DOI":"10.1021\/acs.jmedchem.0c00035","article-title":"Discovery of orally bioavailable chromone derivatives as potent and selective BRD4 inhibitors: scaffold hopping, optimization, and pharmacological evaluation","volume":"63","author":"Liu","year":"2020","journal-title":"J Med Chem"},{"key":"10.1016\/j.drudis.2024.103922_b0320","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/j.abb.2015.05.011","article-title":"Receptor-based virtual screening protocol for drug discovery","volume":"582","author":"Cerqueira","year":"2015","journal-title":"Arch Biochem Biophys"},{"key":"10.1016\/j.drudis.2024.103922_b0325","doi-asserted-by":"crossref","first-page":"1047","DOI":"10.1016\/S1359-6446(02)02483-2","article-title":"Structure-based virtual screening: an overview","volume":"7","author":"Lyne","year":"2002","journal-title":"Drug Discov Today"},{"key":"10.1016\/j.drudis.2024.103922_b0330","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2023.115476","article-title":"Highlights on U.S. FDA-approved fluorinated drugs over the past five years (2018-2022)","volume":"256","author":"Ali","year":"2023","journal-title":"Eur J Med Chem"},{"key":"10.1016\/j.drudis.2024.103922_b0335","doi-asserted-by":"crossref","first-page":"1354","DOI":"10.2174\/1568026618666181010101922","article-title":"Proteolysis targeting chimera (PROTAC): a paradigm-shifting approach in small molecule drug discovery","volume":"18","author":"Wang","year":"2018","journal-title":"Curr Top Med Chem"},{"key":"10.1016\/j.drudis.2024.103922_b0340","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/j.ddtec.2019.01.002","article-title":"Proteolysis targeting chimeras (PROTACs) - past, present and future","volume":"31","author":"Pettersson","year":"2019","journal-title":"Drug Discov Today Technol"},{"key":"10.1016\/j.drudis.2024.103922_b0345","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1080\/17460441.2023.2187777","article-title":"Novel approaches to targeted protein degradation technologies in drug discovery","volume":"18","author":"Xue","year":"2023","journal-title":"Expert Opin Drug Discov"},{"key":"10.1016\/j.drudis.2024.103922_b0350","doi-asserted-by":"crossref","first-page":"938","DOI":"10.1021\/acs.jmedchem.0c02235","article-title":"Discovery of the first druggable GPR52 antagonist to treat Huntington's disease","volume":"64","author":"Komatsu","year":"2021","journal-title":"J Med Chem"},{"key":"10.1016\/j.drudis.2024.103922_b0355","doi-asserted-by":"crossref","first-page":"927","DOI":"10.1021\/acscentsci.6b00280","article-title":"Protein degradation by in-cell self-assembly of proteolysis targeting chimeras","volume":"2","author":"Lebraud","year":"2016","journal-title":"ACS Cent Sci"},{"key":"10.1016\/j.drudis.2024.103922_b0360","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1021\/cn100008c","article-title":"Moving beyond rules: the development of a central nervous system multiparameter optimization (CNS MPO) approach to enable alignment of druglike properties","volume":"1","author":"Wager","year":"2010","journal-title":"ACS Chem Neurosci"},{"key":"10.1016\/j.drudis.2024.103922_b0365","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1021\/cn200100h","article-title":"Knowledge-based, central nervous system (CNS) lead selection and lead optimization for CNS drug discovery","volume":"3","author":"Ghose","year":"2012","journal-title":"ACS Chem Neurosci"}],"container-title":["Drug Discovery Today"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1359644624000473?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1359644624000473?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,23]],"date-time":"2025-10-23T13:11:56Z","timestamp":1761225116000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1359644624000473"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,4]]},"references-count":73,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2024,4]]}},"alternative-id":["S1359644624000473"],"URL":"https:\/\/doi.org\/10.1016\/j.drudis.2024.103922","relation":{},"ISSN":["1359-6446"],"issn-type":[{"value":"1359-6446","type":"print"}],"subject":[],"published":{"date-parts":[[2024,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Orphan GPR52 as an emerging neurotherapeutic target","name":"articletitle","label":"Article Title"},{"value":"Drug Discovery Today","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.drudis.2024.103922","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"103922"}}